- Home
- CMDB vs CADL Comparison
CMDB vs CADL Comparison
Compare CMDB & CADL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CMDB | CADL |
|---|---|---|
| Founded | 2023 | 1999 |
| Country | Monaco | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 342.8M | 339.8M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | CMDB | CADL |
|---|---|---|
| Price | $15.94 | $6.13 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $19.43 |
| AVG Volume (30 Days) | 39.7K | ★ 731.5K |
| Earning Date | 02-12-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $799,159,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 152.53 | N/A |
| 52 Week Low | $8.46 | $4.25 |
| 52 Week High | $17.57 | $13.68 |
Technical Indicators
Market Signals| Indicator | CMDB | CADL |
|---|---|---|
| Relative Strength Index (RSI) | 61.21 | 53.90 |
| Support Level | $14.91 | $5.91 |
| Resistance Level | $15.45 | $6.62 |
| Average True Range (ATR) | 0.43 | 0.36 |
| MACD | 0.06 | -0.00 |
| Stochastic Oscillator | 85.97 | 50.68 |
Price Performance
Historical ComparisonAbout CMDB Costamare Bulkers Holdings Limited
Costamare Bulkers Holdings Ltd is an international owner and operator of dry bulk vessels providing multinational transportation of dry bulk commodities for a broad range of customers. Its owned fleet consists of 38 vessels, with a total carrying capacity of approximately 3,017,000 dwt. The company's vessels transport a broad range of bulks across the shipping routes around the world. Iron ore, coal and grain constitute the majority of its cargoes.
About CADL Candel Therapeutics Inc.
Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.